

2024, Publikationserhebung, Allgemeine Pathologie Heidelberg

Rot: Erst/Letztautorenschaft

*geteilte Erst- oder Letztautorenschaft

PEER- REVIEWED PUBLICATIONS

1. Acker F, Klein A, Rasokat A, Eisert A, Kron A, Christopoulos P, **Stenzinger A**, Kulhavy J, Hummel HD, Waller CF, Hummel A, Rittmeyer A, Kropf-Sanchen C, Zimmermann H, Lörsch A, Kauffmann-Guerrero D, Schütz M, Herster F, Thielert F, Demes M, Althoff FC, Aguinarte L, Heinzen S, Rost M, Schulte H, Stratmann J, Rohde G, Büttner R, Wolf J, Sebastian M, Michels S; National Network Genomic Medicine Lung Cancer. Multicenter Real-World Analysis of Combined MET and EGFR Inhibition in Patients With Non-Small Cell Lung Cancer and Acquired MET Amplification or Polysomy After EGFR Inhibition. *Clin Lung Cancer*. 2024 Dec;25(8):672-682.e5. (IF 3.3)
2. Ackermann S, Herold M, Rohrbacher V, Schäfer M, **Tóth M, Thomann S**, Hackert T, Ryschich E. *In Situ* Immunofluorescence Imaging of Vital Human Pancreatic Tissue Using Fiber-Optic Microscopy. *Int J Biomed Imaging*. 2024 Jun 6;2024:1397875. (IF 3.3)
3. Alashkar Alhamwe B, Yuskaeva K, Wulf F, Trinkmann F, **Kriegsmann M**, Thomas M, Keber CU, Strandmann EPV, Herth FJ, Kolahian S, Renz H, Muley T. Peripheral Inflammation Featuring Eosinophilia or Neutrophilia Is Associated with the Survival and Infiltration of Eosinophils within the Tumor among Various Histological Subgroups of Patients with NSCLC. *Int J Mol Sci*. 2024 Sep 3;25(17):9552. (IF 4.9)
4. Alirezaie N, Chong AL, **Kommoss FKF**, Sabbaghian N, Camacho Valenzuela J, Pelletier D, Nadaf J, Kolekar SB, Sivapalan P, Evans MG, Thorner PS, Fiset PO, von Deimling A, Foulkes WD. Exomic and epigenomic analysis of pulmonary blastoma. *Lung Cancer*. 2024 Sep;195:107916. (IF 4.5)
5. An J*, Kurilov R*, Peccerella T, **Bergmann F**, Edderkaoui M, Lim A, Zhou X, Pfütze K, Schulz A, Wolf S, Hu K, Springfield C, Mughal SS, Zezlina L, Fortunato F, Beyer G, Mayerle J, Roth S, Hulkkonen J, Merz D, Ei S, Mehrabi A, Loos M, Al-Saeedi M, Michalski CW, Büchler MW, Hackert T, Brors B, Pandol SJ, Bailey P, Neoptolemos JP. Metavert synergises with standard cytotoxics in human PDAC organoids and is associated with transcriptomic signatures of therapeutic response. *Transl Oncol*. 2024 Nov;49:102109. (IF 4.5)
6. Arekatla G, Skylaki S, Corredor Suarez D, Jackson H, **Schapiro D**, Engler S, Auler M, Camargo Ortega G, Hastreiter S, Reimann A, Loeffler D, Bodenmiller B, Schroeder T. Identification of an embryonic differentiation stage marked by Sox1 and FoxA2 co-expression using combined cell tracking and high dimensional protein imaging. *Nat Commun*. 2024 Sep 9;15(1):7860. (IF 14.7)
7. Assal RA, Abd El-Bary RBE, Youness RA, Abdelrahman MM, Zahran H, Hosny KA, Esmat G, **Breuhahn K**, El-Ekiaby N, Fawzy IO, Abdelaziz AI. OncomiR-181a promotes carcinogenesis by repressing the extracellular matrix proteoglycan decorin in hepatocellular carcinoma. *BMC Gastroenterol*. 2024 Sep 30;24(1):337. (IF 2.5)
8. Avranas K, Eisenbach C, **Flechtenmacher C**, Korosoglou G. Diagnostic Pathway From Incidental Mass to Metastatic Melanoma: Role of Multimodal Imaging and Medical Therapy. *JACC Case Rep*. 2024 Jan 3;29(1):102146. (IF 21,7)

9. **Ball M, Ourailidis I, Kluck K, Menzel M, Kirchner M, Allgäuer M, Tay TKY, Schnecko F, Volckmar AL, Goldschmid H, Neuman O, Fröhling S, Schirmacher P, Budczies J, Stenzinger A, Kazdal D.** Leveraging Off-Target Reads in Panel Sequencing for Homologous Recombination Repair Deficiency Screening in Tumor. *J Mol Diagn.* 2024 Jun;26(6):479-486. (IF 3.4)
10. Bischoff P*, Reck M*, Overbeck T, Christopoulos P, Rittmeyer A, Lüders H, Kollmeier J, Kulhavy J, Kemper M, Reinmuth N, Röper J, Janning M, Sommer L, Aguinarte L, Koch M, Wiesweg M, Wessler C, Waller CF, Kauffmann-Guerrero D, **Stenzinger A**, Stephan-Falkenau S, Trautmann M, Lassmann S, Tiemann M, Klauschen F, Sebastian M, Griesinger F, Wolf J, Loges S, Frost N; National Network Genomic Medicine Lung Cancer (nNGM) Collaborator Group. Outcome of First-Line Treatment With Pembrolizumab According to KRAS/TP53 Mutational Status for Nonsquamous Programmed Death-Ligand 1-High ($\geq 50\%$) NSCLC in the German National Network Genomic Medicine Lung Cancer. *J Thorac Oncol.* 2024 May;19(5):803-817. (IF 21.0)
11. Bitzer M, Groß S, Albert J, Blödt S, Boda-Heggemann J, Brunner T, Caspari R, De Toni E, Dombrowski F, Evert M, Follmann M, Freudenberger P, Gani C, Geier A, Gkika E, Götz M, Helmberger T, Hoffmann RT, Huppert P, Krug D, Fougère C, Lang H, Langer T, Lenz P, Lüdde T, Mahnken A, Nadalin S, Nguyen HHP, Nothacker M, Ockenga J, Oldhafer K, Paprottka P, Pereira P, Persigehl T, Plentz R, Pohl J, Recken H, Reimer P, Riemer J, Ritterbusch U, Roeb E, Rüssel J, Schellhaas B, **Schirmacher P**, Schlitt HJ, Schmid I, Schuler A, Seehofer D, Sinn M, Stengel A, Steubesand N, Stoll C, Tannapfel A, Taubert A, Tholen R, Trojan J, van Thiel I, Vogel A, Vogl T, Wacker F, Waidmann O, Wedemeyer H, Wege H, Wildner D, Wörns MA, Galle P, Malek N. S3-Leitlinie „Diagnostik und Therapie des Hepatozellulären Karzinoms“ – Langversion 4.0. *Z Gastroenterol.* 2024 Jan;62(1):e67-e161. German (IF 1.4)
12. Bitzer M, Groß S, Albert J, Blödt S, Boda-Heggemann J, Brunner T, Caspari R, De Toni E, Dombrowski F, Evert M, Follmann M, Freudenberger P, Gani C, Geier A, Gkika E, Götz M, Helmberger T, Hoffmann RT, Huppert P, Krug D, Fougère C, Lang H, Langer T, Lenz P, Lüdde T, Mahnken A, Nadalin S, Nguyen HHP, Nothacker M, Ockenga J, Oldhafer K, Paprottka P, Pereira P, Persigehl T, Plentz R, Pohl J, Recken H, Reimer P, Riemer J, Ritterbusch U, Roeb E, Rüssel J, Schellhaas B, **Schirmacher P**, Schlitt HJ, Schmid I, Schuler A, Seehofer D, Sinn M, Stengel A, Steubesand N, Stoll C, Tannapfel A, Taubert A, Tholen R, Trojan J, van Thiel I, Vogel A, Vogl T, Wacker F, Waidmann O, Wedemeyer H, Wege H, Wildner D, Wörns MA, Galle P, Malek N. S3-Leitlinie „Diagnostik und Therapie biliärer Karzinome“ – Kurzversion. *Z Gastroenterol.* 2024 Feb;62(2):231-260. German. (IF 1.4)
13. Blasi M, Kuon J, Lüders H, Misch D, Kauffmann-Guerrero D, Hilbrandt M, **Kazdal D**, Falkenstern-Ge RF, Hackanson B, Dintner S, Faehling M, **Kirchner M**, **Volckmar AL**, Kopp HG, **Allgäuer M**, Grohé C, Tufman A, Reck M, Frost N, **Stenzinger A**, Thomas M, Christopoulos P. Corrigendum to "First-line immunotherapy for lung cancer with MET exon 14 skipping and the relevance of TP53 mutations" [*Eur J Cancer* 199 (2024) 113556]. *Eur J Cancer.* 2024 Jul;205:114130. (IF 7.6)
14. Böning S, Schneider F, Huber AK, Langhoff D, Lin H, Kaczorowski A, **Stenzinger A**, Hohenfellner M, Duensing S, Duensing A. Region of interest localization, tissue storage time, and antibody binding density—a technical note on the GeoMx® Digital Spatial Profiler. *Immuno-oncol Technol.* 2024 Aug 20;23:100727. (IF 5.4)
15. **Budczies J, Romanovsky E, Kirchner M, Neumann O, Blasi M, Schnorbach J, Shah R, Bozorgmehr F, Savai R, Stiewe T, Peters S, Schirmacher P, Thomas M, Kazdal D, Christopoulos P, Stenzinger A.** KRAS and TP53 co-mutation predicts benefit of immune checkpoint blockade in lung adenocarcinoma. *Br J Cancer.* 2024 Aug;131(3):524-533. (IF 6.4)
16. Calina TG, Perez E, Grafenhorst E, Benhamida J, Schallenberg S, Popescu A, Koch I, Janik T, Chen B, Ihlow J, **Roessler S**, Goepfert B, Sinn B, Bahra M, Calin GA, Taube ET, Pelzer U, Neumann CCM, Horst D, Knutsen E, Capper D, Dragomir MP. DNA methylation classifier to diagnose

- pancreatic ductal adenocarcinoma metastases from different anatomical sites. *Clin Epigenetics*. 2024 Nov 10;16(1):156. (IF 4.8)
17. Campos Mármol MC, Aguado M, Ramón Y Cajal T, Gallardo A, Catasús L, Gonzalez A, Méndez JE, Lasa A, Arumi M, Gallego Rubio O, Serra JB, Muñoz Hernandez F, von Deimling A, **Kommoss FKF**, Espinosa I. Non-C19MC-altered embryonal tumor with multilayered rosettes in a young woman with DICER1 syndrome: case report and review of the literature. *Pathologica*. 2024 Jun;116(3):170-175. (IF 4.4)
 18. Chang HY, Dermawan J, Sharma A, Dickson B, Turashvili G, Torrence D, Nucci M, Chiang S, Oliva E, **Kirchner M, Stenzinger A, Mechttersheimer G**, Antonescu C. Sarcomas With RAD51B Fusions Are Associated With a Heterogeneous Phenotype. *Mod Pathol*. 2024 Feb;37(2):100402. (IF 7.1)
 19. Conradt G, **Hausser I**, Nyström A. Epidermal or Dermal Collagen VII Is Sufficient for Skin Integrity: Insights to Anchoring Fibril Homeostasis. *J Invest Dermatol*. 2024 Jun;144(6):1301-1310.e7. (IF 5.7)
 20. De Jonghe J*, Opzoomer JW*, Vilas-Zornoza A*, Crane P*, Nilges BS, Vicari M, Lee H, Lara-Astiaso D, Gross T, Morf J, Schneider K, Cudini J, Ramos-Mucci L, Mooijman D, Tiklová K, Salas SM, Langseth CM, Kashikar ND, Roberts CES; **scTrends Consortium**; Lundeberg J, Nilsson M, Shalek AK, Cribbs AP, Taylor-King JP. A community effort to track commercial single-cell and spatial 'omic technologies and business trends. *Nat Biotechnol*. 2024 Jul;42(7):1017-1023. (IF 33.1)
 21. Denkert C, Schneeweiss A, Rey J, Karn T, Hattesoehl A, Weber KE, Rachakonda S, Braun M, Huober J, Jank P, **Sinn HP**, Zahm DM, Felder B, Hanusch C, Teply-Szymanski J, Marmé F, Fehm T, Thomalla J, Sinn BV, Stiewe T, Marczyk M, Blohmer JU, van Mackelenbergh M, Schem C, Staib P, Link T, Müller V, Stickeler E, Stover DG, Solbach C, Metzger-Filho O, Jackisch C, Geyer CE Jr, Fasching PA, Pusztai L, Nekljudova V, Untch M, Loibl S. Molecular adaptation to neoadjuvant immunotherapy in triple-negative breast cancer. *Cell Rep Med*. 2024 Nov 19;5(11):101825. (IF 11.7)
 22. Dernbach G, **Kazdal D**, Ruff L, Alber M, **Romanovsky E**, Schallenberg S, Christopoulos P, **Weis CA**, Muley T, Schneider MA, **Schirmacher P**, Thomas M, Müller KR, **Budczies J, Stenzinger A**, Klauschen F. Dissecting AI-based mutation prediction in lung adenocarcinoma: A comprehensive real-world study. *Eur J Cancer*. 2024 Nov;211:114292. (IF 7.6)
 23. Dropmann A, Alex S, Schorn K, Tong C, Caccamo T, Godoy P, Ilkavets I, Liebe R, Gonzalez D, Hengstler JG, Piiper A, Quagliata L, Matter MS, Waidmann O, Finkelmeier F, Feng T, Weiss TS, Rahbari N, Birgin E, Rasbach E, **Roessler S, Breuhahn K, Tóth M**, Ebert MP, Dooley S, Hammad S, Meindl-Beinker NM. The TGF- β 1 target WISP1 is highly expressed in liver cirrhosis and cirrhotic HCC microenvironment and involved in pro- and anti-tumorigenic effects. *Biochem Biophys Res Commun*. 2024 Nov 5;732:150409. (IF 2.5)
 24. Eden M*, Leye M*, Hahn J, Heilein E, Luzarowski M, Völschow B, Tannert C, Sossalla S, **Lucena-Porcel C**, Frank D, Frey N. Mst4, a novel cardiac STRIPAK complex-associated kinase, regulates cardiomyocyte growth and survival and is upregulated in human cardiomyopathy. *J Biol Chem*. 2024 May;300(5):107255. (IF 4.0)
 25. Edsjö A, Russnes HG, Lehtiö J, Tamborero D, Hovig E, **Stenzinger A**, Rosenquist R; PCM4EU consortium. High-throughput molecular assays for inclusion in personalised oncology trials - State-of-the-art and beyond. *J Intern Med*. 2024 Jun;295(6):785-803 (IF 9.0)
 26. El Nahhas OSM, Loeffler CML, Carrero ZI, van Treeck M, Kolbinger FR, Hewitt KJ, Muti HS, Graziani M, Zeng Q, Calderaro J, Ortiz-Brüchle N, Yuan T, Hoffmeister M, Brenner H, **Brobeil A**, Reis-Filho JS, Kather JN. Regression-based Deep-Learning predicts molecular biomarkers from pathology slides. *Nat Commun*. 2024 Feb 10;15(1):1253. (IF 14.7)

27. Elwakiel A, Gupta D, Rana R, Manoharan J, Al-Dabet MM, Ambreen S, Fatima S, Zimmermann S, Mathew A, Li Z, Singh K, Gupta A, Pal S, Sulaj A, Kopf S, **Schwab C**, Baber R, Geffers R, Götze T, Alo B, Lamers C, Kluge P, Kuenze G, Kohli S, Renné T, Shahzad K, Isermann B. Factor XII signaling via uPAR-integrin $\beta 1$ axis promotes tubular senescence in diabetic kidney disease. *Nat Commun.* 2024 Sep 11;15(1):7963. (IF 14.7)
28. **Englert N, Schwab C, Legnar M, Weis CA.** Presenting the framework of the whole slide image file Babel fish: An OCR-based file labeling tool. *J Pathol Inform.* 2024 Oct 23;15:100402. (IF 2.66)
29. Gallage S, Ali A, Barragan Avila JE, Seymen N, Ramadori P, Joerke V, Zimare L, Aicher D, Gopalsamy IK, Fong W, Kosla J, Focaccia E, Li X, Yousuf S, Sijmonsma T, Rahbari M, Kommos KS, Billeter A, Prokosch S, Rothermel U, Mueller F, Hetzer J, Heide D, Schinkel B, Machauer T, Pichler B, Malek NP, **Longerich T**, Roth S, Rose AJ, Schwenck J, Trautwein C, Karimi MM, Heikenwalder M. A 5:2 intermittent fasting regimen ameliorates NASH and fibrosis and blunts HCC development via hepatic PPAR α and PCK1. *Cell Metab.* 2024 Jun 4;36(6):1371-1393.e7. (IF 27.7)
30. Gegner HM, Naake T, Aljakouch K, Dugourd A, Kliewer G, Müller T, Schilling D, Schneider MA, Kunze-Rohrbach N, **Grünwald TGP**, Hell R, Saez-Rodriguez J, Huber W, Poschet G, Krijgsveld J. A single-sample workflow for joint metabolomic and proteomic analysis of clinical specimens. *Clin Proteomics.* 2024 Jul 5;21(1):49. (IF 2.8)
31. Glemser PA*, Freitag M*, Kovacs B, Netzer N, Dimitrakopoulou-Strauss A, Haberkorn U, Maier-Hein K, **Schwab C**, Duensing S, Beuthien-Baumann B, Schlemmer HP, Bonekamp D, Giesel F, Sachpekidis C. Enhancing the diagnostic capacity of [^{18}F]PSMA-1007 PET/MRI in primary prostate cancer staging with artificial intelligence and semi-quantitative DCE: an exploratory study. *EJNMMI Rep.* 2024 Nov 8;8(1):37. (IF 1.7)
32. Gerber TS, Ridder DA, Goepfert B, **Brobeil A**, Stenzel P, Zimmer S, Jäkel J, Metzger MO, Schwab R, Martin SZ, Kiss A, **Bergmann F, Schirmacher P**, Galle PR, Lang H, Roth W, Straub BK. N-cadherin: A diagnostic marker to help discriminate primary liver carcinomas from extrahepatic carcinomas. *Int J Cancer.* 2024 May 15;154(10):1857-1868. (IF 5.7)
33. Grass A*, Kasajima A*, Foersch S, **Kriegsmann M, Brobeil A**, Schmitt M, Wagner D, Poppinga J, Wiese D, Maurer E, Kirschbaum A, Muley T, Winter H, Rinke A, Gress TM, Kremer M, Evert M, Märkl B, Quaas A, Eckstein M, Tschurtschenthaler M, Klöppel G, Denkert C, Bartsch DK*, Jesinghaus M*. PITX2 as a Sensitive and Specific Marker of Midgut Neuroendocrine Tumors: Results from a Cohort of 1157 Primary Neuroendocrine Neoplasms. *Mod Pathol.* 2024 Apr;37(4):100442. (IF 7.1)
34. **Grimsrud MM, Forster M, Goepfert B, Hemmrich-Stanisak G, Sax I, Grzyb K, Braadland PR, Charbel A, Metzger C, Albrecht T, Steiert TA, Schlesner M, Manns MP, Vogel A, Yaqub S, Karlsen TH, Schirmacher P, Boberg KM, Franke A, Roessler S*, Folseraas T*.** Whole-exome sequencing reveals novel cancer genes and actionable targets in biliary tract cancers in primary sclerosing cholangitis. *Hepatol Commun.* 2024 Jul 5;8(7):e0461. (IF 5.6)
35. Groß S, Bitzer M, Albert J, Blödt S, Boda-Heggemann J, Brunner T, Caspari R, De Toni E, Dombrowski F, Evert M, Follmann M, Freudenberger P, Gani C, Geier A, Gkika E, Götz M, Helmberger T, Hoffmann RT, Huppert P, Krug D, Fougère C, Lang H, Langer T, Lenz P, Lüdde T, Mahnken A, Nadalin S, Nguyen HHP, Nothacker M, Ockenga J, Oldhafer K, Paprottka P, Pereira P, Persigehl T, Plentz R, Pohl J, Recken H, Reimer P, Riemer J, Ritterbusch U, Roeb E, Rüssel J, Schellhaas B, **Schirmacher P**, Schlitt HJ, Schmid I, Schuler A, Seehofer D, Sinn M, Stengel A, Steubesand N, Stoll C, Tannapfel A, Taubert A, Tholen R, Trojan J, van Thiel I, Vogel A, Vogl T, Wacker F, Waidmann O, Wedemeyer H, Wege H, Wildner D, Wörns MA, Galle P, Malek N. S3-

- Leitlinie „Diagnostik und Therapie des Hepatozellulären Karzinoms“ – Kurzversion. *Z Gastroenterol.* 2024 Jan;62(1):73-109. German. (IF 1.4)
36. Groß S, Bitzer M, Albert J, Blödt S, Boda-Heggemann J, Brunner T, Caspari R, De Toni E, Dombrowski F, Evert M, Follmann M, Freudenberger P, Gani C, Geier A, Gkika E, Götz M, Helmberger T, Hoffmann RT, Huppert P, Krug D, La Fougère C, Lang H, Langer T, Lenz P, Lüdde T, Mahnken A, Nadalin S, Nguyen HHP, Nothacker M, Ockenga J, Oldhafer K, Paprottka P, Pereira P, Persigehl T, Plentz R, Pohl J, Recken H, Reimer P, Riemer J, Ritterbusch U, Roeb E, Rüssel J, Schellhaas B, **Schirmacher P**, Schlitt HJ, Schmid I, Schuler A, Seehofer D, Sinn M, Stengel A, Steubesand N, Stoll C, Tannapfel A, Taubert A, Tholen R, Trojan J, van Thiel I, Vogel A, Vogl T, Wacker F, Waidmann O, Wedemeyer H, Wege H, Wildner D, Wörns MA, Galle P, Malek N. S3-Leitlinie „Diagnostik und Therapie biliärer Karzinome“ – Langversion 4.0. *Z Gastroenterol.* 2024 Feb;62(2):e213-e282. German. (IF 1.4)
 37. **Grünwald TGP**, Postel-Vinay S, Nakayama RT, Berlow NE, Bolzicco A, Cerullo V, Dermawan JK, Frezza AM, Italiano A, Jin JX, Le Loarer F, Martin-Broto J, Pecora A, Perez-Martinez A, Tam YB, Tirode F, Trama A, Pasquali S, Vescia M, Wortmann L, Wortmann M, Yoshida A, Webb K, Huang PH, Keller C, Antonescu CR. Translational Aspects of Epithelioid Sarcoma: Current Consensus. *Clin Cancer Res.* 2024 Mar 15;30(6):1079-1092. (IF 10.0)
 38. Gustav M, Reitsam NG, Carrero ZI, Loeffler CML, van Treeck M, Yuan T, West NP, Quirke P, Brinker TJ, Brenner H, Favre L, Märkl B, **Stenzinger A**, **Brobeil A**, Hoffmeister M, Calderaro J, Pujals A, Kather JN. Deep learning for dual detection of microsatellite instability and POLE mutations in colorectal cancer histopathology. *NPJ Precis Oncol.* 2024 May 23;8(1):115. (IF 6.8)
 39. Hasselbring F, Herth FJF, **Kriegsmann M**, Kriegsmann K, Eberhardt R. Transbronchial Cryobiopsy Using the Ultrathin 1.1-mm Cryoprobe with Ultrathin Bronchoscopy under Radial Endobronchial Ultrasound Guidance for Diagnosis of Peripheral Pulmonary Lesions. *Respiration.* 2024;103(5):268-274. (IF 3.5)
 40. Hilgers L, Ghaffari Laleh N, West NP, Westwood A, Hewitt KJ, Quirke P, Grabsch HI, Carrero ZI, Matthaei E, Loeffler CML, Brinker TJ, Yuan T, Brenner H, **Brobeil A**, Hoffmeister M, Kather JN. Automated curation of large-scale cancer histopathology image datasets using deep learning. *Histopathology.* 2024 Jun;84(7):1139-1153. (IF 3.9)
 41. Hoegen-Saßmannshausen P, Naumann P, Hoffmeister-Wittmann P, Ben Harrabi S, Seidensaal K, Weykamp F, Mielke T, Ellerbrock M, Habermehl D, Springfield C, Dill MT, **Longerich T**, **Schirmacher P**, Mehrabi A, Chang DH, Hörner-Rieber J, Jäkel O, Haberer T, Combs SE, Debus J, Herfarth K, Liermann J. Carbon ion radiotherapy of hepatocellular carcinoma provides excellent local control: The prospective phase I PROMETHEUS trial. *JHEP Rep.* 2024 Mar 11;6(6):101063. (IF 9.5)
 42. **Hofmann K***, Hofmann S*, Weigl F, Mai J, Schreiner S. DMSO and Its Role in Differentiation Impact Efficacy of Human Adenovirus (HAdV) Infection in HepaRG Cells. *Viruses.* 2024 Apr 19;16(4):633. (IF 3.8)
 43. Huber AK, Kaczorowski A, Schneider F, Böning S, Görtz M, Langhoff D, **Schwab C**, **Stenzinger A**, Hohenfellner M, Duensing A, Duensing S. Digital spatial profiling identifies the tumor center as a topological niche in prostate cancer characterized by an upregulation of BAD. *Sci Rep.* 2024 Aug 31;14(1):20281. (IF 3.8)
 44. Hummel M, Hielscher T, Emde-Rajaratnam M, Salwender H, **Beck S**, Scheid C, Bertsch U, Goldschmidt H, Jauch A, Moreaux J, Seckinger A, Hose D. Quantitative Integrative Survival Prediction in Multiple Myeloma Patients Treated With Bortezomib-Based Induction, High-Dose Therapy and Autologous Stem Cell Transplantation. *JCO Precis Oncol.* 2024 Jul;8:e2300613. (IF 5.3)

45. Jahangir CA, Page DB, Broeckx G, Gonzalez CA, Burke C, Murphy C, Reis-Filho JS, Ly A, Harms PW, Gupta RR, Vieth M, Hida AI, Kahila M, Kos Z, van Diest PJ, Verbandt S, Thagaard J, Khroya R, Abduljabbar K, Acosta Haab G, Acs B, Adams S, Almeida JS, Alvarado-Cabrero I, Azmoudeh-Ardalan F, Badve S, Baharun NB, Bellolio ER, Bheemaraju V, Blenman KR, Botinelly Mendonça Fujimoto L, Burgues O, Chardas A, Cheang MCU, Ciompi F, Cooper LA, Coosemans A, Corredor G, Dantas Portela FL, Deman F, Demaria S, Dudgeon SN, Elghazawy M, Fernandez-Martín C, Fineberg S, Fox SB, Giltmane JM, Gnjatic S, Gonzalez-Ericsson PI, Grigoriadis A, Halama N, Hanna MG, Harbhajanka A, Hart SN, Hartman J, Hewitt S, Horlings HM, Husain Z, Irshad S, Janssen EA, Kataoka TR, Kawaguchi K, Khramtsov AI, Kiraz U, Kirtani P, Kodach LL, Korski K, Akturk G, Scott E, Kovács A, Laenkholm AV, Lang-Schwarz C, Larsimont D, Lennerz JK, Lerousseau M, Li X, Madabhushi A, Maley SK, Manur Narasimhamurthy V, Marks DK, McDonald ES, Mehrotra R, Michiels S, Kharidehal D, Minhas FUAA, Mittal S, Moore DA, Mushtaq S, Nighat H, Papatomas T, Penault-Llorca F, Perera RD, Pinard CJ, Pinto-Cardenas JC, Pruneri G, Puztai L, Rajpoot NM, Rapoport BL, Rau TT, Ribeiro JM, Rimm D, Vincent-Salomon A, Saltz J, Sayed S, Hytopoulos E, Mahon S, Siziopikou KP, Sotiriou C, **Stenzinger A**, Sughayer MA, Sur D, Symmans F, Tanaka S, Taxter T, Tejpar S, Teuwen J, Thompson EA, Tramm T, Tran WT, van der Laak J, Verghese GE, Viale G, Wahab N, Walter T, Waumans Y, Wen HY, Yang W, Yuan Y, Bartlett J, Loibl S, Denkert C, Savas P, Loi S, Specht Stovgaard E, Salgado R, Gallagher WM, Rahman A. Image-based multiplex immune profiling of cancer tissues: translational implications. A report of the International Immuno-oncology Biomarker Working Group on Breast Cancer. *J Pathol.* 2024 Mar;262(3):271-288. (IF 5.6)
46. Jamieson A, Grube M, **Kommoss F**, Lum A, Leung S, Chiu D, Henderson G, Heitz F, Heublein S, Zeimet AG, Hasenburg A, Diebold J, Walter C, Staebler A, Reynolds J, Lapuk A, McConechy MK, Huntsman DG, Gilks B, Kommoss S, McAlpine JN. Validation and clinical performance of a single test, DNA based endometrial cancer molecular classifier. *Int J Gynecol Cancer.* 2024 Dec 2;34(12):1888-1897. (IF 4.1)
47. Jank P, Karn T, van Mackelenbergh M, Lindner J, Treue D, Huober J, Engels K, Solbach C, Diebold K, Marmé F, Müller V, Schneeweiss A, **Sinn HP**, Fehm T, Schem C, Stickeler E, Fasching P, **Budczies J**, Felder B, Nekljudova V, Holtschmidt J, Untch M, Denkert C, Loibl S. An Analysis of PIK3CA Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials. *Clin Cancer Res.* 2024 Sep 3;30(17):3868-3880. (IF 10.0)
48. Jiang X*, Baig AH*, Palazzo G, Del Pizzo R, Bortecen T, Groessl S, Zaal EA, Amaya Ramirez CC, Kowar A, Aviles-Huerta D, Berkers CR, Palm W, **Tschaharganeh D**, Krijgsveld J, Loayza-Puch F. P53-dependent hypusination of eIF5A affects mitochondrial translation and senescence immune surveillance. *Nat Commun.* 2024 Aug 28;15(1):7458. (IF 14.7)
49. Jiang X, Hoffmeister M, Brenner H, Muti HS, Yuan T, Foersch S, West NP, **Brobeil A**, Jonnagaddala J, Hawkins N, Ward RL, Brinker TJ, Saldanha OL, Ke J, Müller W, Grabsch HI, Quirke P, Truhn D, Kather JN. End-to-end prognostication in colorectal cancer by deep learning: a retrospective, multicentre study. *Lancet Digit Health.* 2024 Jan;6(1):e33-e43. Erratum in: *Lancet Digit Health.* 2024 Jul;6(7):e445. (IF 23.8)
50. Jin D, Liang S, Shmatko A, Arnold A, Horst D, **Grünewald TGP**, Gerstung M, Bai X. Teacher-student collaborated multiple instance learning for pan-cancer PDL1 expression prediction from histopathology slides. *Nat Commun.* 2024 Apr 9;15(1):3063. (IF 14.7)
51. Kälber KA, Winkler JK, Toberer F, Stojković M, **Mechtersheimer G**, Hoffmann J. Zunehmend schmerzhaftes Induration des Daumens [Increasingly painful induration of the thumb]. *Dermatologie (Heidelb).* 2024 Jul;75(7):592-594. German. (IF 0.8)

52. Keggenhoff FL*, Castven D*, Becker D, Stojkovic S, Castven J, Zimpel C, Straub BK, Gerber T, Langer H, Hähnel P, Kindler T, Fahrer J, O'Rourke CJ, Ehmer U, Saborowski A, Ma L, Wang XW, Gaiser T, Matter MS, Sina C, Derer S, Lee JS, **Roessler S**, Kaina B, Andersen JB, Galle PR, Marquardt JU. PARP-1 selectively impairs KRAS-driven phenotypic and molecular features in intrahepatic cholangiocarcinoma. *Gut*. 2024 Sep 9;73(10):1712-1724. (IF 23.0)
53. Khanal R, Heinen N, Bogomolova A, Meister TL, Herrmann ST, Westhoven S, Nocke MK, Todt D, Jockenhövel F, **Klein IM, Hartmann L**, Vondran FWR, Steinmann E, Zimmer G, Ott M, Brown RJP, Sharma AD, Pfaender S. MicroRNAs modulate SARS-CoV-2 infection of primary human hepatocytes by regulating the entry factors ACE2 and TMPRSS2. *Liver Int*. 2024 Nov;44(11):2983-2995. (IF 6.0)
54. Kim YR*, Joo J*, Lee HJ, Kim C, Park JC, Yu YS, Kim CR, Lee DH, Cha J, Kwon H, Hanssen KM, **Grünewald TGP**, Choi M, Han I, Bae S, Jung I, Shin Y, Baek SH. Prion-like domain mediated phase separation of ARID1A promotes oncogenic potential of Ewing's sarcoma. *Nat Commun*. 2024 Aug 3;15(1):6569. (IF 14.7)
55. Kippenberger M, Schönberg G, Kaczorowski A, Schneider F, Böning S, Sun A, **Schwab C**, Görtz M, Schütz V, **Stenzinger A**, Hohenfellner M, Duensing A, Duensing S. Immune landscape of renal cell carcinoma with metastasis to the pancreas. *Urol Oncol*. 2024 Nov;42(11):373.e9-373.e17. (IF 2.4)
56. Klotz LV, Weigert A, Eichhorn F, **Allgäuer M**, Muley T, Shah R, Savai R, Eichhorn ME, Winter H. Impact of T Cell Ratios on Survival in Pleural Mesothelioma: Insights from Tumor Microenvironment Analysis. *Cancers (Basel)*. 2024 Oct 8;16(19):3418. (IF 4.5)
57. Klümper N, Tran NK, Zschäbitz S, Hahn O, Büttner T, Roghmann F, Bolenz C, Zengerling F, **Schwab C**, Nagy D, Toma M, Kristiansen G, Heers H, Ivanyi P, Niegisch G, Grunewald CM, Darr C, Farid A, Schlack K, Abbas M, Aydogdu C, Casuscelli J, Mokry T, Mayr M, Niedersüß-Beke D, Rausch S, Dietrich D, Saal J, Ellinger J, Ritter M, Alajati A, Kuppe C, Meeks J, Vera Badillo FE, Nakauma-González JA, Boormans J, Junker K, Hartmann A, Grünwald V, Hölzel M, Eckstein M. *NECTIN4* Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer. *J Clin Oncol*. 2024 Jul 10;42(20):2446-2455. (IF 42.1)
58. Köbel M, Kang EY, Lee S, Ogilvie T, Terzic T, Wang L, Wiebe NJ, Al-Shamma Z, Cook LS, Nelson GS, Stewart CJ, von Deimling A, **Kommoss FK**, Lee CH. Mesonephric-type adenocarcinomas of the ovary: prevalence, diagnostic reproducibility, outcome, and value of PAX2. *J Pathol Clin Res*. 2024 Jul;10(4):e12389. (IF 3.4)
59. Koek G, Schmitz SM, Bednarsch J, Heise D, **Longerich T**, Bakers F, Trautwein C, Luedde T, Ulmer TF, Neumann UP. Living-Donor Liver Transplantation for a Large Hepatocellular Carcinoma in a Genetically Identical Twin Sister. *Z Gastroenterol*. 2024 Jan;62(1):56-61. (IF 1.4)
60. Komlosi K, Glocker C, Hsu-Rehder HH, Alter S, Kopp J, Hotz A, Zimmer AD, **Hausser I**, Sandhoff R, Oji V, Fischer J. Autosomal Dominant Lamellar Ichthyosis Due to a Missense Variant in the Gene *NKPD1*. *J Invest Dermatol*. 2024 Dec;144(12):2754-2763.e6. (IF 5.7)
61. **Kommoss FK**, Lee CH, Tessier-Cloutier B, Gilks CB, Stewart CJ, von Deimling A, Köbel M. Mesonephric-like adenocarcinoma harbours characteristic copy number variations and a distinct DNA methylation signature closely related to mesonephric adenocarcinoma of the cervix. *J Pathol*. 2024 Jan;262(1):4-9. (IF 5.6)
62. **Kommoss FKF, Charbel A**, Kolin DL, Howitt BE, Köbel M, Lee JC, McCluggage WG, Agaimy A, Dickson BC, von Deimling A, Lee CH. Uterine mesenchymal tumours harboring the *KAT6B/A::KANSL1* gene fusion represent a distinct type of uterine sarcoma based on DNA methylation profiles. *Virchows Arch*. 2024 Nov;485(5):793-803. (IF 3.4)
63. **Kommoss FKF**, Chong AS, Apellaniz-Ruiz M, Turashvili G, Park KJ, Hanley K, Valera ET, von Deimling A, Vujanic G, McCluggage WG, Foulkes WD. Teratoma-associated and so-called pure

- Wilms tumour of the ovary represent two separate tumour types with distinct molecular features. *Histopathology*. 2024 Mar;84(4):683-696. (IF 3.9)
64. Kopp J*, Jahn D*, Vogt G*, Psoma A, Ratto E, Morelle W, Stelzer N, **Hausser I**, Hoffmann A, de Los Santos MR, Koch LA, Fischer-Zirnsak B, Thiel C, Palm W, Meierhofer D, van den Bogaart G, Foulquier F, Meinhardt A, Kornak U. Golgi pH elevation due to loss of V-ATPase subunit V0a2 function correlates with tissue-specific glycosylation changes and globozoospermia. *Cell Mol Life Sci*. 2024 Dec 16;82(1):4. (IF 6.2)
65. **Krieg S, Rohde T, Rausch T, Butthof L, Wendler-Link L, Eckert C, Breuhahn K, Galy B, Korbel J, Billmann M, Breinig M, Tschaharganeh DF**. Mitoferrin2 is a synthetic lethal target for chromosome 8p deleted cancers. *Genome Med*. 2024 Jun 17;16(1):83. (IF 10.4)
66. Kuric M, **Beck S**, Schneider D, Rindt W, Evers M, Meißner-Weigl J, Zeck S, Krug M, Herrmann M, Hartmann TN, Leich E, Rudert M, Docheva D, Seckinger A, Hose D, Jundt F, Ebert R. Modeling Myeloma Dissemination In Vitro with hMSC-interacting Subpopulations of INA-6 Cells and Their Aggregation/Detachment Dynamics. *Cancer Res Commun*. 2024 Apr 29;4(4):1150-1164. (IF 2.0)
67. Lerma-Martin C, Badia-I-Mompel P, Ramirez Flores RO, Sekol P, Schäfer PSL, Riedl CJ, Hofmann A, Thäwel T, Wünnemann F, Ibarra-Arellano MA, Trobisch T, Eisele P, **Schapiro D**, Haeussler M, Hametner S, Saez-Rodriguez J, Schirmer L. Cell type mapping reveals tissue niches and interactions in subcortical multiple sclerosis lesions. *Nat Neurosci*. 2024 Dec;27(12):2354-2365. (IF 21.1)
68. Levy T*, Voeltzke K*, Hruby L*, Alasad K*, Bas Z, Snaebjörnsson M, Marciano R, Scharov K, Planque M, Vriens K, Christen S, Funk CM, Hassiepen C, Kahler A, Heider B, Picard D, Lim JKM, Stefanski A, Bendrin K, Vargas-Toscano A, Kahlert UD, Stühler K, Remke M, Elkabets M, **Grünwald TGP**, Reichert AS, Fendt SM, Schulze A, Reifenberger G, Rotblat B, Leprivier G. mTORC1 regulates cell survival under glucose starvation through 4EBP1/2-mediated translational reprogramming of fatty acid metabolism. *Nat Commun*. 2024 May 14;15(1):4083. (IF 14.7)
69. **Liu K, Wehling L, Wan S, Weiler SME, Tóth M, Ibberson D, Marhenke S, Ali A, Lam M, Guo T, Pinna F, Pedrini F, Damle-Vartak A, Dropmann A, Rose F, Colucci S, Cheng W, Bissinger M, Schmitt J, Birner P, Poth T, Angel P, Dooley S, Muckenthaler MU, Longerich T, Vogel A, Heikenwälder M, Schirmacher P, Breuhahn K**. Dynamic YAP expression in the non-parenchymal liver cell compartment controls heterologous cell communication. *Cell Mol Life Sci*. 2024 Mar 4;81(1):115. (IF 6.2)
70. Longuespée R, Kunz J, Fresnais M, Foerster KI, Burhenne J, Thomas M, **Kazdal D, Stenzinger A**, Christopoulos P, Haefeli WE. Therapeutic drug monitoring of osimertinib in non-small cell lung cancer and short bowel syndrome: A case report. *Br J Clin Pharmacol*. 2024 Jan;90(1):344-349. (IF 3.4)
71. Lonsdorf AS, Edelmann D, **Albrecht T, Brobeil A**, Labrenz J, Johanning M, Schlenk RF, **Goeppert B**, Enk AH, Toberer F. Differential Immunoexpression of Inhibitory Immune Checkpoint Molecules and Clinicopathological Correlates in Keratoacanthoma, Primary Cutaneous Squamous Cell Carcinoma and Metastases. *Acta Derm Venereol*. 2024 Feb 7;104:adv13381. (IF 3.5)
72. Majlesara A, Golriz M, Ramouz A, Khajeh E, Hackert T, Strobel O, Adeliasedehi A, Aminizadeh E, Chang DH, Wielpütz MO, **Goeppert B**, Merle U, Mieth M, Büchler MW, Mehrabi A. Portal vein arterialization as a salvage method in advanced hepatopancreatobiliary surgery. *Br J Surg*. 2024 Mar 2;111(3):znae053. (IF 8.6)
73. Manoharan J, Rana R, Kuenze G, Gupta D, Elwakiel A, Ambreen S, Wang H, Banerjee K, Zimmermann S, Singh K, Gupta A, Fatima S, Kretschmer S, Schaefer L, Zeng-Brouwers J, **Schwab**

- C, Al-Dabet MM, Gadi I, Altmann H, Koch T, Poitz DM, Baber R, Kohli S, Shahzad K, Geffers R, Lee-Kirsch MA, Kalinke U, Meiler J, Mackman N, Isermann B. Tissue factor binds to and inhibits interferon- α receptor 1 signaling. *Immunity*. 2024 Jan 9;57(1):68-85.e11. (IF 25.5)
74. Martins LR, Sieverling L, Michelhans M, Schiller C, Erkut C, **Grünwald TGP**, Triana S, Fröhling S, Velten L, Glimm H, Scholl C. Single-cell division tracing and transcriptomics reveal cell types and differentiation paths in the regenerating lung. *Nat Commun*. 2024 Mar 12;15(1):2246. (IF 14.7)
75. Mayer P, Hausen A, Steinle V, **Bergmann F**, Kauczor HU, Loos M, Roth W, Klauss M, Gaida MM. The radiomorphological appearance of the invasive margin in pancreatic cancer is associated with tumor budding. *Langenbecks Arch Surg*. 2024 May 29;409(1):167. (IF 2.1)
76. **Menzel M, Kirchner M, Kluck K, Ball M, Beck S, Allgäuer M, Assmann C, Schnorbach J, Volckmar AL, Tay TKY, Goldschmid H, Tan DS, Thomas M, Kazdal D, Budczies J, Stenzinger A, Christopoulos P**. Genomic heterogeneity at baseline is associated with T790M resistance mutations in EGFR-mutated lung cancer treated with the first-/second-generation tyrosine kinase inhibitors. *J Pathol Clin Res*. 2024 Mar;10(2):e354. (IF 3.4)
77. **Menzel M, Martis-Thiele M, Goldschmid H, Ott A, Romanovsky E, Siemanowski-Hrach J, Seillier L, Brüchele NO, Maurer A, Lehmann KV, Begemann M, Elbracht M, Meyer R, Dintner S, Claus R, Meier-Kolthoff JP, Blanc E, Möbs M, Joosten M, Benary M, Basitta P, Hölscher F, Tischler V, Groß T, Kutz O, Prause R, William D, Horny K, Goering W, Sivalingam S, Borkhardt A, Blank C, Junk SV, Yasin L, Moskalev EA, Carta MG, Ferrazzi F, Tögel L, Wolter S, Adam E, Matysiak U, Rosenthal T, Dönitz J, Lehmann U, Schmidt G, Bartels S, Hofmann W, Hirsch S, Dikow N, Göbel K, Banan R, Hamelmann S, Fink A, Ball M, Neumann O, Rehker J, Kloth M, Murtagh J, Hartmann N, Jurmeister P, Mock A, Kumbrink J, Jung A, Mayr EM, Jacob A, Trautmann M, Kirmse S, Falkenberg K, Ruckert C, Hirsch D, Immel A, Dietmaier W, Haack T, Marienfeld R, Fürstberger A, Niewöhner J, Gerstenmaier U, Eberhardt T, Greif PA, Appenzeller S, Maurus K, Doll J, Jelting Y, Jonigk D, Märkl B, Beule D, Horst D, Wulf AL, Aust D, Werner M, Reuter-Jessen K, Ströbel P, Auber B, Sahm F, Merkelbach-Bruse S, Siebolts U, Roth W, Lassmann S, Klauschen F, Gaisa NT, Weichert W, Evert M, Armeanu-Ebinger S, Ossowski S, Schroeder C, Schaaf CP, Malek N, Schirmacher P, Kazdal D, Pfarr N, Budczies J, Stenzinger A**. Benchmarking whole exome sequencing in the German network for personalized medicine. *Eur J Cancer*. 2024 Nov;211:114306. (IF 7.6)
78. Michal M, Agaimy A, Croce S, **Mechtersheimer G**, Gross JM, Xing D, Bell DA, Gupta S, Mosaieby E, Martínek P, Klubíčková N, Michalová K, Bouda J, Fínek J, Hernandez T, Michal M, Schoolmeester JK*, Ondič O*. PLAG1-Rearranged Uterine Sarcomas: A Study of 11 Cases Showing a Wide Phenotypical Spectrum Not Limited to Myxoid Leiomyosarcoma-Like Morphology. *Mod Pathol*. 2024 Sep;37(9):100552. (IF 7.1)
79. Minnai F, Noci S, Esposito M, Schneider MA, Kobinger S, Eichhorn M, Winter H, Hoffmann H, **Kriegsmann M**, Incarbone MA, Mattioni G, Tosi D, Muley T, Dragani TA, Colombo F. Germline Polymorphisms Associated with Overall Survival in Lung Adenocarcinoma: Genome-Wide Analysis. *Cancers (Basel)*. 2024 Sep 25;16(19):3264. (IF 4.5)
80. Mitzlaff K, Kirstein MM, Müller C, Venerito M, Olkus A, Dill MT, Weinmann A, Kocheise L, Busch A, Schulze K, Allo G, Waldschmidt DT, Barsch M, Bengsch B, Quante M, Gonzalez-Carmona MA, Himmelsbach V, Finkelmeier F, Kloeckner R, **Schirmacher P**, Marquardt JU, Zimpel C. Efficacy, safety and differential outcomes of immune-chemotherapy with gemcitabine, cisplatin and durvalumab in patients with biliary tract cancers: A multicenter real world cohort. *United European Gastroenterol J*. 2024 Nov;12(9):1230-1242. (IF 5.8)

81. Monji-Azad S, Männle D, Hesser J, Pohlmann J, Rotter N, Affolter A, **Weis CA**, Ludwig S, Scherl C. Point Cloud Registration for Measuring Shape Dependence of Soft Tissue Deformation by Digital Twins in Head and Neck Surgery. *Biomed Hub*. 2024 Jan 9;9(1):9-15. (no IF)
82. Moratin J, Horn D, Oehme M, Semmelmayr K, **Flechtenmacher C**, Ristow O, Held T, Engel M, Hoffmann J, Freudlsperger C. Variation of resection margins in oral cancer in dependence of tumor stage and subsite - a retrospective cohort study. *Clin Oral Investig*. 2024 May 20;28(6):327. (IF 3.1)
83. Mosele MF, Westphalen CB, **Stenzinger A**, Barlesi F, Bayle A, Bièche I, Bonastre J, Castro E, Dienstmann R, Krämer A, Czarnecka AM, Meric-Bernstam F, Michiels S, Miller R, Normanno N, Reis-Filho J, Remon J, Robson M, Rouleau E, Scarpa A, Serrano C, Mateo J, André F. Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group. *Ann Oncol*. 2024 Jul;35(7):588-606. doi: 10.1016/j.annonc.2024.04.005. Erratum in: *Ann Oncol*. 2025 Feb 20:S0923-7534(24)04947-0. (IF 56.7)
84. Moura MS, Costa J, Velasco V, **Kommoss F**, Oliva E, Le Loarer F, McCluggage WG, Razack R, Treilleux I, Mills A, Longacre T, Devouassoux-Shisheboran M, Hostein I, Azmani R, Blanchard L, Hartog C, Soubeyran I, Khalifa E, Croce S. Pan-TRK immunohistochemistry in gynaecological mesenchymal tumours: diagnostic implications and pitfalls. *Histopathology*. 2024 Feb;84(3):451-462. (IF 3.9)
85. Muley T, Herth FJ, Heussel CP, **Kriegsmann M**, Thomas M, Meister M, Schneider MA, Wehnl B, Mang A, Holdenrieder S. Prognostic value of tumor markers ProGRP, NSE and CYFRA 21-1 in patients with small cell lung cancer and chemotherapy-induced remission. *Tumour Biol*. 2024;46(s1):S219-S232. (IF 1.8)
86. Muley T, Schneider MA, Meister M, Thomas M, Heußel CP, **Kriegsmann M**, Holdenrieder S, Wehnl B, Rolny V, Mang A, Gerber R, Herth F. CYFRA 21-1, CA 125 and CEA provide additional prognostic value in NSCLC patients with stable disease at first CT scan. *Tumour Biol*. 2024;46(s1):S163-S175. (1.8)
87. Musa J, Kochendoerfer SM, Willis F, Sauerteig C, Harnoss JM, Rompen IF, **Grünewald TGP**, Al-Saeedi M, Schneider M, Harnoss JC. The GIST of it all: management of gastrointestinal stromal tumors (GIST) from the first steps to tailored therapy. A bibliometric analysis. *Langenbecks Arch Surg*. 2024 Mar 14;409(1):95. (IF 2.1)
88. Nikitina E, Burk-Körner A, Wiesenfarth M, Alwers E, Heide D, Tessmer C, Ernst C, Kronic D, Schrotz-King P, Chang-Claude J, **von Winterfeld M**, **Herpel E**, **Brobeil A**, Brenner H, Heikenwalder M, Hoffmeister M, Kopp-Schneider A, Bund T. Bovine meat and milk factor protein expression in tumor-free mucosa of colorectal cancer patients coincides with macrophages and might interfere with patient survival. *Mol Oncol*. 2024 May;18(5):1076-1092. (IF 5.0)
89. **Ohmura S, Grünewald TGP. Optimizing ATR Inhibition and Cisplatin Synergy in Ewing Sarcoma. Clin Cancer Res. 2024 Aug 15;30(16):3358-3360. (IF 10.0)**
90. Olkus A, **Tomczak A**, Berger AK, Rauber C, Puchas P, Wehling C, **Longerich T**, Mehrabi A, Chang DH, Liermann J, Schäfer S, Pfeiffenberger J, Jäger D, Michl P, Springfeld C, Dill MT. Durvalumab Plus Gemcitabine and Cisplatin in Patients with Advanced Biliary Tract Cancer: An Exploratory Analysis of Real-World Data. *Target Oncol*. 2024 Mar;19(2):213-221. (IF 7.6)
91. Park-Simon TW, Müller V, Albert US, Banyas Paluchowski M, Bauerfeind I, Blohmer JU, Budach W, Dall P, Ditsch N, Fallenberg EM, Fasching PA, Fehm T, Friedrich M, Gerber B, Gluz O, Harbeck N, Hartkopf AD, Heil J, Huober J, Jackisch C, Kolberg-Liedtke C, Kreipe HH, Krug D, Kühn T, Kümmel S, Loibl S, Lüftner D, Lux MP, Maass N, Mundhenke C, Reimer T, Rhiem K, Rody A, Schmidt M, Schneeweiss A, Schütz F, **Sinn HP**, Solbach C, Solomayer EF, Stickeler E, Thomssen

- C, Untch M, Witzel I, Wuerstlein R, Wöckel A, Janni W, Thill M. Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2024. *Breast Care (Basel)*. 2024 Jun;19(3):165-182. (IF 2.0)
92. Pfarr N, von Schwarzenberg K, Zocholl D, Merkelbach-Bruse S, Siemanowski J, Mayr EM, Herold S, Kleo K, Heukamp LC, Willing EM, **Menzel M**, Lehmann U, Bartels S, Chakraborty S, Baretton G, Demes MC, Döring C, **Kazdal D**, **Budczies J**, Rad R, Wild P, Christinat Y, McKee T, **Schirmacher P**, Horst D, Büttner R, **Stenzinger A**, Sehouli J, Vollbrecht C, Hummel M, Braicu EI, Weichert W; German HRD assay Harmonization Consortium. High Concordance of Different Assays in the Determination of Homologous Recombination Deficiency-Associated Genomic Instability in Ovarian Cancer. *JCO Precis Oncol*. 2024 Mar;8:e2300348. (IF 5.3)
93. **Pfeffer T***, **Krug SM***, **Kracke T**, **Schürfeld R**, **Colbatzky F**, **Kirschner P**, **Medert R**, **Freichel M**, **Schumacher D**, **Bartosova M**, **Zarogiannis SG**, **Muckenthaler MU**, **Altamura S**, **Pezer S**, **Volk N**, **Schwab C**, **Duensing S**, **Fleming T**, **Heidenreich E**, **Zschocke J**, **Hell R**, **Poschet G**, **Schmitt CP***, **Peters V.*** Knock-out of dipeptidase CN2 in human proximal tubular cells disrupts dipeptide and amino acid homeostasis and para- and transcellular solute transport. *Acta Physiol (Oxf)*. 2024 Apr;240(4):e14126. (IF 5.6)
94. Pires C, Saramago A, Moura MM, Li J, Donato S, Marques IJ, Belo H, Machado AC, Cabrera R, **Grünewald TGP**, Leite V, Cavaco BM. Identification of Germline *FOXE1* and Somatic *MAPK* Pathway Gene Alterations in Patients with Malignant Struma Ovarii, Cleft Palate and Thyroid Cancer. *Int J Mol Sci*. 2024 Feb 6;25(4):1966. (IF 4.9)
95. Plum PS*, Hess T*, Bertrand D*, Morgenstern I, Velazquez Camacho O, Jonas C, Alidousty C, Wagner B, **Roessler S**, **Albrecht T**, Becker J, Richartz V, Holz B, Hoppe S, Poh HM, Chia BKH, Chan CX, Pathiraja T, Teo AS, Marquardt JU, Khng A, Heise M, Fei Y, Thieme R, Klein S, Hong JH, Dima SO, Popescu I, Hoppe-Lotichius M, Buettner R, Lautem A, Otto G, Quaas A, Nagarajan N, Rozen S, Teh BT, Goepfert B, Drebber U, Lang H, Tan P, Gockel I, Schumacher J, Hillmer AM. Integrative genomic analyses of European intrahepatic cholangiocarcinoma: Novel ROS1 fusion gene and PBX1 as prognostic marker. *Clin Transl Med*. 2024 Jun;14(6):e1723. (IF 7.9)
96. Pouyiourou M, Bochtler T, Coith C, Wikman H, Kraft B, Hielscher T, **Stenzinger A**, Riethdorf S*, Pantel K*, Krämer A*. Frequency and Prognostic Value of Circulating Tumor Cells in Cancer of Unknown Primary. *Clin Chem*. 2024 Jan 4;70(1):297-306. (IF 7.1)
97. Qian X, Klatt S, Bennewitz K, Wohlfart DP, Lou B, Meng Y, Buettner M, Poschet G, Morgenstern J, Fleming T, Sticht C, **Hausser I**, Fleming I, Szendroedi J, Nawroth PP, Kroll J. Impaired Detoxification of Trans, Trans-2,4-Decadienal, an Oxidation Product from Omega-6 Fatty Acids, Alters Insulin Signaling, Gluconeogenesis and Promotes Microvascular Disease. *Adv Sci (Weinh)*. 2024 Jan;11(4):e2302325. (IF 14.3)
98. Reimold P, Tosev G, Kaczorowski A, Friedhoff J, **Schwab C**, Schütz V, Görtz M, Panzer N, Heller M, Aksoy C, Himmelsbach R, Walle T, Zschäbitz S, Jäger D, Duensing A, **Stenzinger A**, Hohenfellner M, Duensing S. PD-L1 as a Urine Biomarker in Renal Cell Carcinoma-A Case Series and Proof-of-Concept Study. *Diagnostics (Basel)*. 2024 Mar 30;14(7):741. (IF 3.0)
99. Richtmann S, Marwitz S, Muley T, Koistinen H, Christopoulos P, Thomas M, **Kazdal D**, **Allgäuer M**, Winter H, Goldmann T, Meister M, Klingmüller U, Schneider MA. The pregnancy-associated protein glycodelin as a potential sex-specific target for resistance to immunotherapy in non-small cell lung cancer. *Transl Res*. 2024 Oct;272:177-189. (IF 6.4)
100. Roeb E, Canbay A, Bantel H, Bojunga J, de Laffolie J, Demir M, Denzer UW, Geier A, Hofmann WP, Hudert C, Karlas T, Krawczyk M, **Longerich T**, Lüdde T, Roden M, Schattenberg JM, Sterneck M, Tannapfel A, Lorenz P, Tacke F; Collaborators. Amendment „Neue Nomenklatur zur MASLD (Metabolic Dysfunction Associated Steatotic Liver Disease; metabolische Dysfunktion assoziierte steatotische Lebererkrankung)“ zur S2k-Leitlinie „Nicht-alkoholische

- Fettlebererkrankung“ (v.2.0/April 2022) der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS). *Z Gastroenterol.* 2024 Jul;62(7):1077-1087. German. (IF 1.4)
101. Röhrich M, Daum J, **Gutjahr E**, Spektor AM, Glatting FM, Sahin YA, Buchholz HG, Hoppner J, Schroeter C, Mavriopoulou E, Schlamp K, Grott M, Eichhorn F, Heußel CP, Kauczor HU, Kreuter M, Giesel F, Schreckenberger M, Winter H, Haberkorn U. Diagnostic Potential of Supplemental Static and Dynamic ⁶⁸Ga-FAPI-46 PET for Primary ¹⁸F-FDG-Negative Pulmonary Lesions. *J Nucl Med.* 2024 Jun 3;65(6):872-879. (IF 9.1)
 102. Roider T*, Baertsch MA*, Fitzgerald D, Vöhringer H, Brinkmann BJ, Czernilofsky F, Knoll M, Llaó-Cid L, Mathioudaki A, Faßbender B, Herbon M, Lautwein T, Bruch PM, Liebers N, Schürch CM, Passerini V, Seifert M, **Brobeil A**, **Mechtersheimer G**, Müller-Tidow C, Weigert O, Seiffert M, Nolan GP, Huber W, Dietrich S. Multimodal and spatially resolved profiling identifies distinct patterns of T cell infiltration in nodal B cell lymphoma entities. *Nat Cell Biol.* 2024 Mar;26(3):478-489. (IF 17.3)
 103. Romero P, Burger A, Wennberg E, Schmitteckert S, Holland-Cunz S, **Schwab C**, Günther P. Clinical Relevance of Pathological Diagnosis of Hirschsprung's Disease with Acetylcholine-Esterase Histochemistry or Calretinin Immunohistochemistry. *Children (Basel).* 2024 Apr 3;11(4):428. (IF 2.0)
 104. Rompen IF, Schütte I, Crnovrsanin N, Schiefer S, Billeter AT, Haag GM, **Longerich T**, Czigany Z, Schmidt T, Billmann F, Sisic L, Nienhüser H. Prognostic Relevance of the Proximal Resection Margin Distance in Distal Gastrectomy for Gastric Adenocarcinoma. *Ann Surg Oncol.* 2024 Oct;31(10):6900-6908. (IF 3.4)
 105. Rompen IF, Schütte I, Crnovrsanin N, Schiefer S, Billeter AT, Haag GM, **Longerich T**, Czigany Z, Schmidt T, Billmann F, Sisic L, Nienhüser H. ASO Author Reflections: The Prognostic Relevance of the Proximal Resection Margin Distance is Dependent upon the Histological Subtype of Gastric Adenocarcinoma. *Ann Surg Oncol.* 2024 Oct;31(10):6974-6975. (IF 3.4)
 106. **Rusche D**, **Englert N**, **Runz M**, **Hetjens S**, **Langner C**, **Gaiser T**, **Weis, CA**. **Unraveling a Histopathological Needle-in-Haystack Problem: Exploring the Challenges of Detecting Tumor Budding in Colorectal Carcinoma Histology.** *Appl. Sci.* 2024; 14 (2): 949. (IF 2.5)
 107. Saalfeld FC, Möller J, Christopoulos P, Wenzel C, Rasokat A, Wang XA, Vathiotis I, König D, Illini O, Grohé C, Wiesweg M, Wesseler C, Schubart C, Pelusi N, Rohde G, Overbeck TR, Kirfel J, Alt J, Kauffmann-Guerrero D, Griesinger F, Kulhavy J, **Allgäuer M**, Klimova A, Schütz M, Aust DE, Hochmair MJ, Rothschild SI, Syrigos KN, Veluswamy R, Michels S, **Stenzinger A**, Jöhrens K, Wermke M. Small cell transformation in EGFR-mutated non-small cell lung cancer: DLL3 expression and efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with chemotherapy. *Eur J Cancer.* 2024 Dec;213:115065. (IF 7.6)
 108. Safi S*, Gysan MR*, Weber D, Behnisch R, Muley T, **Allgäuer M**, Winter H, Hoffmann H, Eichhorn M. Peri- and postoperative morbidity and mortality in older patients with non-small cell lung cancer: a matched-pair study. *World J Surg Oncol.* 2024 Aug 8;22(1):213. (IF 2.5)
 109. Scherr AL, Nader L, Xu K, Elssner C, Ridder DA, Nichetti F, Mastel M, Fritzsche S, Kelmendi E, Schmitt N, Hoffmeister-Wittmann P, **Weiler SME**, Korell F, **Albrecht T**, Schwab M, Isele H, Kessler A, Hüllein J, Seretny A, Ye L, Urbanik T, Welte S, Leblond AL, Heilig CE, Rahbari M, Ali A, Gallage S, Lenoir B, Wilhelm N, Gärtner U, Ogradnik SJ, Springfield C, **Tschaharganeh D**, Fröhling S, **Longerich T**, Schulze-Bergkamen H, Jäger D, Brandl L, **Schirmacher P**, Straub BK, Weber A, De Toni EN, **Goepfert B**, Heikenwalder M, Jackstadt R, **Roessler S**, **Breuhahn K**, Köhler BC. Etiology-independent activation of the LTβ-LTβR-RELB axis drives aggressiveness and predicts poor prognosis in HCC. *Hepatology.* 2024 Aug 1;80(2):278-294. (IF 12.9)

110. Schlieben LD, Achleitner MT, Bourke B, Diesner M, Feichtinger RG, Fichtner A, **Flechtenmacher C**, Hadzic N, Hegarty R, Heilos A, Janecke A, Konstantopoulou V, Lenz D, Mayr JA, Müller T, Prokisch H, Vogel GF. Missense variants in the TRPM7 α -kinase domain are associated with recurrent pediatric acute liver failure. *Hepatology*. 2024 Nov 29;8(12):e0598. (IF 5.6)
111. Schmäche T, Fohgrub J, Klimova A, Laaber K, Drukewitz S, Merboth F, Hennig A, Seidlitz T, Herbst F, Baenke F, Ada AM, Groß T, Wenzel C, Ball CR, Praetorius C, Schmidt T, Ringelband-Schilling B, Koschny R, **Stenzinger A**, Roeder I, Jaeger D, Zeissig S, Welsch T, Aust D, Glimm H, Folprecht G, Weitz J*, Haag GM*, Stange DE*. Stratifying esophago-gastric cancer treatment using a patient-derived organoid-based threshold. *Mol Cancer*. 2024 Jan 10;23(1):10. (IF 27.7)
112. Schmithals C*, Kakoschky B*, Denk D*, von Harten M*, Klug JH, Hintermann E, Dropmann A, Hamza E, Jacomin AC, Marquardt JU, Zeuzem S, **Schirmacher P**, Herrmann E, Christen U, Vogl TJ, Waidmann O, Dooley S, Finkelmeier F, Piiper A. Tumour-specific activation of a tumour-blood transport improves the diagnostic accuracy of blood tumour markers in mice. *EBioMedicine*. 2024 Jul;105:105178. (IF 9.7)
113. Schostak M, Bradbury A, Briganti A, Gonzalez D, Gomella L, Mateo J, Penault-Llorca F, **Stenzinger A**, Wyatt AW, Bjartell A. Practical Guidance on Establishing a Molecular Testing Pathway for Alterations in Homologous Recombination Repair Genes in Clinical Practice for Patients with Metastatic Prostate Cancer. *Eur Urol Oncol*. 2024 Jun;7(3):344-354. (IF 8.3)
114. Schrader A, Netzer N, Hielscher T, Görtz M, Zhang KS, Schütz V, **Stenzinger A**, Hohenfellner M, Schlemmer HP, Bonekamp D. Prostate cancer risk assessment and avoidance of prostate biopsies using fully automatic deep learning in prostate MRI: comparison to PI-RADS and integration with clinical data in nomograms. *Eur Radiol*. 2024 Dec;34(12):7909-7920. (IF 4.7)
115. Siebolts U*, Pappesch R*, Bauer M, Dietmaier W, Ernst M, Haak A, Hartmann N, Iilm K, Kalbournz S, Krause T, **Kazdal D**, Schorle H, Utpatel K, Merkelbach-Bruse S. High success rate of first proficiency testing for RET fusions and RET mutations in lung and thyroid cancer samples by various methods. *Virchows Arch*. 2024 Sep;485(3):519-526. (IF 3.4)
116. Soon GST, Callea F, Burt AD, Cook S, Terracciano L, Ercan C, Dienes HP, Goodman ZD, Roberts EA, Clouston AD, Gouw ASH, Kleiner DE, Park YN, Chung T, **Schirmacher P**, Tiniakos D, Dimopoulou K, Weber A, Endhardt K, Torbenson M. Steatohepatic hepatocellular carcinoma: A new approach to classifying morphological subtypes of hepatocellular carcinoma. *Hum Pathol*. 2024 Jul;149:55-65. (IF 2.7)
117. Speel EM, Dafni U, Thunnissen E, Hendrik Rüschoff J, O'Brien C, Kowalski J, Kerr KM, Bubendorf L, Sansano I, Joseph L, **Kriegsmann M**, Navarro A, Monkhorst K, Bille Madsen L, Hernandez Losa J, Biernat W, **Stenzinger A**, Rüländ A, Hillen LM, Marti N, Molina-Vila MA, Dellaporta T, Kammler R, Peters S, Stahel RA, Finn SP, Radonic T; Lungscape Consortium (see Appendix). ROS1 fusions in resected stage I-III adenocarcinoma: Results from the European Thoracic Oncology Platform Lungscape project. *Lung Cancer*. 2024 Aug;194:107860. (IF 4.5)
118. **Spektor AM***, **Gutjahr E***, Lang M, Glatting FM, Hackert T, Pausch T, Tjaden C, Schreckenberger M, Haberkorn U, Röhrich M. Immunohistochemical FAP Expression Reflects ^{68}Ga -FAP PET Imaging Properties of Low- and High-Grade Intraductal Papillary Mucinous Neoplasms and Pancreatic Ductal Adenocarcinoma. *J Nucl Med*. 2024 Jan 2;65(1):52-58. (IF 9.1)
119. Stauber RE, Rautou PE, Stefanescu H, Horhat A, Thiele M, Lackner C; **SALVE Histopathology Group**. Validation of NIAAam-CRP criteria to predict alcohol-associated steatohepatitis on liver histology. *JHEP Rep*. 2024 Mar 7;6(5):101055. (IF 9.5)
120. Stenzel PJ, Schindeldecker M, Seidmann L, **Herpel E**, Hohenfellner M, Hatiboglu G, Foersch S, Porubsky S, Macher-Goepfing S, Roth W, Tagscherer KE. CD15 Is a Risk Predictor and a Novel Target in Clear Cell Renal Cell Carcinoma. *Pathobiology*. 2024;91(3):219-229. (IF 3.5)

121. **Sugiyanto RN, Metzger C, Inal A, Truckenmueller F, Gür K, Eiteneuer E, Huth T, Fraas A, Heinze I, Kirkpatrick J, Sticht C, Albrecht T, Goepfert B, Poth T, Pusch S, Mehrabi A, Schirmacher P, Ji J, Ori A, Roessler S.** Proteomic profiling reveals CEACAM6 function in driving gallbladder cancer aggressiveness through integrin receptor, PRKCD and AKT/ERK signaling. *Cell Death Dis.* 2024 Oct 28;15(10):780. (IF 8.1)
122. Tessier-Cloutier B*, **Kommoss FKF***, Kolin DL, Němejcová K, Smith D, Pors J, Stewart CJR, McCluggage WG, Foulkes WD, von Deimling A, Köbel M, Lee CH. Dedifferentiated and Undifferentiated Ovarian Carcinoma: An Aggressive and Molecularly Distinct Ovarian Tumor Characterized by Frequent SWI/SNF Complex Inactivation. *Mod Pathol.* 2024 Jan;37(1):100374. (IF 7.1)
123. Thill M, Janni W, Albert US, Banys-Paluchowski M, Bauerfeind I, Blohmer J, Budach W, Dall P, Ditsch N, Fallenberg EM, Fasching PA, Fehm T, Friedrich M, Gerber B, Gluz O, Harbeck N, Hartkopf A, Heil J, Huober J, Jackisch C, Kolberg-Liedtke C, Kreipe HH, Krug D, Kühn T, Kümmel S, Loibl S, Lüftner D, Lux MP, Maass N, Mundhenke C, Reimer T, Rhiem K, Rody A, Schmidt M, Schneeweiss A, Schütz F, **Sinn HP**, Solbach C, Solomayer EF, Stickeler E, Thomssen C, Untch M, Witzel I, Wöckel A, Würstlein R, Müller V, Park-Simon TW. Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2024. *Breast Care (Basel).* 2024 Jun;19(3):183-191. (IF 2.0)
124. **Thomann S, Metzler T, Tóth M, Schirmacher P, Mogler C.** Immunologic landscape of human hepatic hemangiomas and epithelioid hemangioendotheliomas. *Hepatol Commun.* 2024 Jan 11;8(1):e0359. (IF 5.6)
125. Togawa R, Dahm H, Feisst M, **Sinn P**, Hennigs A, Nees J, Pfob A, Schäffgen B, Stieber A, Zivanovic O, Heil J, Golatta M, Riedel F. Evaluation of Ex Vivo Shear Wave Elastography of Axillary Sentinel Lymph Nodes in Patients with Early Breast Cancer. *Cancers (Basel).* 2024 Dec 22;16(24):4270. (IF 4.5)
126. **Tóth M, Kirchner M, Longerich T, Stenzinger A, Schirmacher P.** Integrated genotype-phenotype analysis of familial adenomatous polyposis-associated hepatocellular adenomas. *Virchows Arch.* 2024 Apr;484(4):587-595. (IF 3.4)
127. Tran CS, Kersten J, Yan J, **Breinig M, Huth T, Poth T**, Colasanti O, Riedl T, Faure-Dupuy S, Diehl S, Verhoye L, Li TF, Lingemann M, Schult P, Ahlén G, Frelin L, Kühnel F, Vondran FWR, **Breuhahn K**, Meuleman P, Heikenwälder M, **Schirmacher P**, Bartenschlager R, Laketa V, **Roessler S**, **Tschaharganeh DF**, Sällberg M, Lohmann V. Phosphatidylinositol 4-Kinase III Alpha Governs Cytoskeletal Organization for Invasiveness of Liver Cancer Cells. *Gastroenterology.* 2024 Aug;167(3):522-537. (IF 25.7)
128. Truhn D, Tayebi Arasteh S, Saldanha OL, Müller-Franzes G, Khader F, Quirke P, West NP, Gray R, Hutchins GGA, James JA, Loughrey MB, Salto-Tellez M, Brenner H, **Brobeil A**, Yuan T, Chang-Claude J, Hoffmeister M, Foersch S, Han T, Keil S, Schulze-Hagen M, Isfort P, Bruners P, Kaissis G, Kuhl C, Nebelung S, Kather JN. Encrypted federated learning for secure decentralized collaboration in cancer image analysis. *Med Image Anal.* 2024 Feb;92:103059. (IF 10.7)
129. van Keulen AM, Buettner S, Olthof PB, Klümpen HJ, Erdmann JI, Izquierdo-Sanchez L, Banales JM, **Goepfert B, Roessler S**, Zieniewicz K, Lamarca A, Valle JW, La Casta A, Hoogwater FJH, Donadon M, Scheiter A, Marzioni M, Adeva J, Kiudeliene E, Fernández JMU, Vidili G, Mocan T, Fabris L, Krawczyk M, Folseraas T, Dopazo C, Detry O, Voiosu T, Scripcariu V, Biancaniello F, Braconi C, Macias RIR, Groot Koerkamp B. Comparing Survival of Perihilar Cholangiocarcinoma After R1 Resection Versus Palliative Chemotherapy for Unresected Localized Disease. *Ann Surg Oncol.* 2024 Oct;31(10):6495-6503. (IF 3.4)

130. Vogeser M, Brüggemann M, **Stenzinger A**; AWMF. AWMF statement on medical services in laboratory diagnostics and pathology with regard to the IVDR. *Clin Chem Lab Med*. 2024 Mar 11;62(8):e173-e174. (IF 3.8)
131. Wan S*, He QY*, Yang Y*, Liu F, Zhang X, Guo X, Niu H, Wang Y, Liu YX, Ye WL, Li XM, ZhuanSun XM, Sun P, He XS, Hu G, **Breuhahn K**, Zhao H, Wu GQ, Wu H. SPARC Stabilizes ApoE to Induce Cholesterol-Dependent Invasion and Sorafenib Resistance in Hepatocellular Carcinoma. *Cancer Res*. 2024 Jun 4;84(11):1872-1888. (IF 12.5)
132. **Weiler SME***, **Bissinger M**, **Rose F**, von Bubnoff F, Lutz T, Ori A, **Schirmacher P**, **Breuhahn K***. SEPTIN10-mediated crosstalk between cytoskeletal networks controls mechanotransduction and oncogenic YAP/TAZ signaling. *Cancer Lett*. 2024 Mar 1;584:216637. (IF 9.1) 81368
133. Weißer C, Netzer N, Görtz M, Schütz V, Hielscher T, **Schwab C**, Hohenfellner M, Schlemmer HP, Maier-Hein KH, Bonekamp D. Weakly Supervised MRI Slice-Level Deep Learning Classification of Prostate Cancer Approximates Full Voxel- and Slice-Level Annotation: Effect of Increasing Training Set Size. *J Magn Reson Imaging*. 2024 Apr;59(4):1409-1422. (IF 3.3)
134. **Wesener MC***, **Weiler SME***, **Bissinger M**, **Klessinger TF**, **Rose F**, Merker S, Luzarowski M, Ruppert T, Helm B, Klingmüller U, **Schirmacher P**, **Breuhahn K***. CRKL Enhances YAP Signaling through Binding and JNK/JUN Pathway Activation in Liver Cancer. *Int J Mol Sci*. 2024 Aug 5;25(15):8549. (IF 4.9)
135. Weykamp F, Schaub L, Eichhorn M, Winter H, **Schirmacher P**, Thomas M, Haberkorn U, Ellerbrock M, Adeberg S, Debus J, Herfarth K. Carbon Ion Beam Radiation Therapy as Part of a Trimodal Therapy for Non-small Cell Superior Sulcus Tumors: The INKA Study. *Adv Radiat Oncol*. 2024 Jul 15;9(9):101573. (IF 2.2)
136. Winkler I, Tolkachov A, Lammers F, Lacour P, Daugelaite K, Schneider N, Koch ML, Panten J, Grünschläger F, **Poth T**, Ávila BM, Schneider A, Haas S, Odom DT, Gonçalves Â. The cycling and aging mouse female reproductive tract at single-cell resolution. *Cell*. 2024 Feb 15;187(4):981-998.e25. (IF 45.5)
137. Xu K, Kessler A, Nichetti F, Hoffmeister-Wittmann P, Scherr AL, Nader L, Kelmendi E, Schmitt N, Schwab M, García-Beccaria M, Sobol B, Nieto OA, Isele H, Gärtner U, Vaquero-Siguero N, Volk J, Korell F, Mock A, Heide D, Ramadori P, Lenoir B, **Albrecht T**, Hüllelin J, Jäger D, Fröhling S, Springfield C, Jackstadt R, Heikenwälder M, Dill MT, **Roessler S**, Goepfert B, Köhler BC. Lymphotoxin beta-activated LTBR/NIK/RELB axis drives proliferation in cholangiocarcinoma. *Liver Int*. 2024 Nov;44(11):2950-2963. (IF 6.0)
138. Yuan T, Edelmann D, Kather JN, Fan Z, **Tagscherer KE**, **Roth W**, Beyerle-Hudler M, **Brobeil A**, Kloor M, Bläker H, Burwinkel B, Brenner H, Hoffmeister M. CpG-biomarkers in tumor tissue and prediction models for the survival of colorectal cancer: A systematic review and external validation study. *Crit Rev Oncol Hematol*. 2024 Jan;193:104199. (IF 5.5)
139. Yuan T, Wankhede D, Edelmann D, Kather JN, **Tagscherer KE**, **Roth W**, Beyerle-Hudler M, **Brobeil A**, Kloor M, Bläker H, Brenner H, Hoffmeister M. Large-scale external validation and meta-analysis of gene methylation biomarkers in tumor tissue for colorectal cancer prognosis. *EBioMedicine*. 2024 Jul;105:105223. (IF 9.7)
140. Zhang J, Ji F, Tan Y, Zhao L, Zhao Y, Liu J, Shao L, Shi J, Ye M, He X, Jin J, Zhao B, Huang J, **Roessler S**, Zheng X, Ji J. Oncogenic Roles of Laminin Subunit Gamma-2 in Intrahepatic Cholangiocarcinoma via Promoting EGFR Translation. *Adv Sci (Weinh)*. 2024 Jun;11(21):e2309010. (IF 14.3)
141. Zhang Q, Wei T, Jin W, Yan L, Shi L, Zhu S, Bai Y, Zeng Y, Yin Z, Yang J, Zhang W, Wu M, Zhang Y, Peng G, **Roessler S**, Liu L. Deficiency in SLC25A15, a hypoxia-responsive gene, promotes hepatocellular carcinoma by reprogramming glutamine metabolism. *J Hepatol*. 2024 Feb;80(2):293-308. (IF 26.8)

142. Zhao Y, Xue S, Wei D, Zhang J, Zhang N, Mao L, Liu N, Zhao L, Yan J, Wang Y, Cai X, Zhu S, **Roessler S**, Ji J. Membrane RRM2-positive cells represent a malignant population with cancer stem cell features in intrahepatic cholangiocarcinoma. *J Exp Clin Cancer Res*. 2024 Sep 6;43(1):255. (IF 11.4)
143. Zimmer J, Grieshaber P, **Allgäuer M**, Günther P, Beedgen B, Rauch H, **Stenzinger A**, Gorenflo M, Winter H, Eichhorn M, Loukanov T. Surgical therapy of a Fetal Lung Interstitial Tumor (FLIT) in an infant – A case report and review of surgical considerations. *Surgery Case Reports : Advances and Techniques 2* 2024 Jun 11: 100038 (no IF)
144. Zwirner S, Abu Rmilah AA, Klotz S, Pfaffenroth B, Kloevekorn P, Moschopoulou AA, Schuette S, Haag M, Selig R, Li K, Zhou W, Nelson E, Poso A, Chen H, Amiot B, Jia Y, Minshew A, Michalak G, Cui W, Rist E, **Longerich T**, Jung B, Felgendreff P, Trompak O, Premssirirut PK, Gries K, Muerdter TE, Heinkele G, Wuestefeld T, Shapiro D, Weissbach M, Koenigsrainer A, Sipos B, Ab E, Zacarias MO, Theisgen S, Gruenheit N, Biskup S, Schwab M, Albrecht W, Laufer S, Nyberg S, Zender L. First-in-class MKK4 inhibitors enhance liver regeneration and prevent liver failure. *Cell*. 2024 Mar 28;187(7):1666-1684.e26. (IF 45.5)

REVIEWS AND OTHER PUBLICATIONS

1. Angwin C, Doolan BJ, **Hausser I**, Labine B, Lavallee M, Mackay D, Pope FM, Seneviratne SL, Winship I, Burrows NP. Skin fragility and wound management in Ehlers-Danlos syndromes: a report by the International Consortium on Ehlers-Danlos Syndromes and Hypermobility Spectrum Disorders Skin Working Group. *Clin Exp Dermatol*. 2024 Nov 22;49(12):1496-1503. (IF 3.7)
2. Baretton G, Lordick F; Die Interdisziplinäre Expertengruppe; Gaiser T, Hofheinz R, Horst D, Lorenzen S, Möhler M, Röcken C, **Schirmacher P**, Stahl M, Thuss-Patience P, Tiemann K. Standardisierte und qualitätsgesicherte prädiktive PD-L1-Testung im oberen Gastrointestinaltrakt [Standardized and quality-assured predictive PD-L1 testing in the upper gastrointestinal tract. German version]. *Pathologie (Heidelb)*. 2024 Feb;45(1):51-58. German. (IF 0.9)
3. **Bochtler T, Becker H, Stenzinger A**. „Cancer of unknown primary“-histologische und molekularpathologische Grundlagen in der Diagnostik. *Die Onkologie*. 2024;30(Suppl 5): 188-195. German. (IF 0.2)
4. **Budczies J*, Kazdal D*, Menzel M, Beck S, Kluck K, Altbürger C, Schwab C, Allgäuer M, Ahadova A, Kloor M, Schirmacher P, Peters S, Krämer A, Christopoulos P, Stenzinger A**. Tumour mutational burden: clinical utility, challenges and emerging improvements. *Nat Rev Clin Oncol*. 2024 Oct;21(10):725-742. (IF 81.1)
5. Clouston AD, Gouw ASH, Tiniakos D, Bedossa P, Brunt EM, Callea F, Dienes HP, Goodman ZD, Hubscher SG, Kakar S, Kleiner DE, Lackner C, Park YN, Roberts EA, **Schirmacher P**, Terracciano L, Torbenson M, Wanless IR, Zen Y, Burt AD. Severe acute liver disease in adults: Contemporary role of histopathology. *Histopathology*. 2024 Oct;85(4):549-561. (IF 3.9)
6. De Jonghe J, Opzoomer JW, Vilas-Zornoza A, Nilges BS, Crane P, Vicari M, Lee H, Lara-Astiaso D, Gross T, Morf J, Schneider K, Cudini J, Ramos-Mucci L, Mooijman D, Tiklová K, Salas SM,

- Langseth CM, Kashikar ND; scTrends Consortium; **Schapiro D**, Lundeberg J, Nilsson M, Shalek AK, Cribbs AP, Taylor-King JP. scTrends: A living review of commercial single-cell and spatial 'omic technologies. *Cell Genom.* 2024 Dec 11;4(12):100723. (IF 11.1)
7. Elbracht M, Auber B, Kurth I, Stenzinger A, Schaaf CP, Schroeder C. Humangenetische Diagnostik bei onkologischen Erkrankungen: Bedeutung von Tumorrisikosyndromen für Therapie und Prävention. *Die Onkologie* 2024; 30:10 (922-931). (IF 0.2)
 8. **García-Foncillas J, Arnold D, Avouac B, Lassen U, Laurent-Puig P, Taieb J, Helland Å, Stenzinger A.** Overcoming barriers in biomarker testing. Letter to the Editor regarding: 'ESMO study on the availability and accessibility of biomolecular technologies in oncology in Europe', by A. Bayle et al. *Ann Oncol.* 2024 Jul;35(7):677-678. (IF 56.7)
 9. Hofman P, Berezowska S, **Kazdal D**, Mograbi B, Ilić M, **Stenzinger A**, Hofman V. Current challenges and practical aspects of molecular pathology for non-small cell lung cancers. *Virchows Arch.* 2024 Feb;484(2):233-246. (IF 3.4)
 10. **Kahles A, Goldschmid H, Volckmar AL, Kazdal D**, Gassner UM, Vogeser M, Brüggemann M, Bürrig KF, Kääh-Sanyal V, **Flechtenmacher C, Schirmacher P, Stenzinger A.** Pathology in the legal framework of European and German medical device law: Operation, use and in-house manufacture of in vitro diagnostic medical devices. *Ger Med Sci.* 2024 Oct 11;22:Doc09. (IF 1.3)
 11. **Kommoss FKF.** Lessons from genomic profiling: towards a molecular-based classification of ovarian Sertoli-Leydig cell tumour. *Histopathology.* 2024 Mar;84(4):712-714. (IF 3.9)
 12. Lehmann U, **Stenzinger A.** Der Biomarker EGFR in der Tumorpathologie [The EGFR biomarker in tumor pathology]. *Pathologie (Heidelb).* 2024 Sep;45(5):344-346. German. (IF 0.9)
 13. Lehmann U, **Stenzinger A.** Der Biomarker POLE in der Tumorpathologie [The biomarker POLE in tumor pathology]. *Pathologie (Heidelb).* 2024 Feb;45(1):67-68. German. (IF 0.9)
 14. **Longerich T, Stenzinger A, Schirmacher P.** Molecular diagnostics of hepatobiliary and pancreatic neoplasias. *Virchows Arch.* 2024 Feb;484(2):263-272. (IF 3.4)
 15. **Poth T, Schirmacher P.** Zentren für experimentelle Tierpathologie besetzen noch immer eine Nischenposition in der translationalen Medizin – Ist es Zeit für eine Veränderung? [Centers for experimental animal pathology still occupy a small but valuable niche in translational medicine-time for change?]. *Pathologie (Heidelb).* 2024 Nov;45(Suppl 1):31-36. German. (IF 0.9)
 16. **Schirmacher P, Longerich T, Schwab C.** Letter to the Editors: "Autopsy-based histopathological characterization of myocarditis after anti-SARS-CoV-2-vaccination" by C. Schwab et al. *Clin Res Cardiol.* 2024 Feb;113(2):356-357. (IF 3.8)
 17. Steiger K, Langer A, **Brobeil A.** Gewebebiobanken – die nächste Generation: qualitätsgesichert, finanziert und integriert? [Next generation tissue biobanking: quality assured, financed, and integrated?]. *Pathologie (Heidelb).* 2024 Nov;45(Suppl 1):47-50. German. (IF 0.9)
 18. **Stenzinger A,** Klauschen F. Forget lung, breast or prostate cancer? Why we shouldn't abandon tumour names yet. *Nature.* 2024 Mar;627(8002):38. (IF 50.5)
 19. **Stenzinger A,** Vogel A, Lehmann U, Lamarca A, Hofman P, Terracciano L, Normanno N. Molecular profiling in cholangiocarcinoma: A practical guide to next-generation sequencing. *Cancer Treat Rev.* 2024 Jan;122:102649. (IF 9.6)
 20. Vogeser M, Brüggemann M, Brandt K, Ceglarek U, Gieskes V, Hitziger N, **Kahles A,** Klar E, Roggenbuck D, Schliephake H, Schulte O, Wettmarshausen S, Zimmermann U, Sack U, **Stenzinger A;** Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e.V. (AWMF). Die EU-Verordnung für In-vitro-Diagnostika (IVDR) in der Praxis: Umsetzung und Anwendung - Ergebnisse einer öffentlichen Veranstaltung der Arbeitsgemeinschaft der

Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) im März 2023. Ger Med Sci. 2024 Jan 29;22:Doc01. (IF 1.3)

21. Wachtel M, Surdez D, **Grünewald TGP**, Schäfer BW. Functional Classification of Fusion Proteins in Sarcoma. Cancers (Basel). 2024 Mar 29;16(7):1355. (IF 4.5)

Book chapters

Schirmacher P, Trauner M, Lackner C, Weber A, Baba H.A., Evert M (2024) Kapitel 33: Leber und intrahepatische Gallenwege. in: Pathologie. Das Lehrbuch. Siebente Auflage. Höfler G, Kreipe H, Moch H (eds.), Elsevier, Deutschland, S. 637-678. ISBN: 978-3-437-42391-8.

Schirmacher P, Jochum W, Lackner C. (2024) Kapitel 34: Gallenblase und extrahepatische Gallenwege. in: Pathologie. Das Lehrbuch. Siebente Auflage. Höfler G, Kreipe H, Moch H (eds.), Elsevier, Deutschland, S. 679-684. ISBN: 978-3-437-42391-8.

Blattgerste C, Herrser J, **Weis, C-A** (2024) Kapitel 1: Extending the margin of pathological tissue using a computer vision pipeline. In : 1st. Joint DFH/UFA workshop on AI in Medicine: Optimised Trials with Machine Learning. Xavier Fresquet, Jürgen Hesser (eds), 2024, Heidelberg University Library, S.4-8